Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study

Dec.05.2022
Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study
Marijuana abuse among US youths has increased by 245% since 2000, while alcohol abuse has steadily declined.

Since 2000, there has been a 245% increase in marijuana abuse among American teenagers, while alcohol abuse has steadily declined during the same period.


According to a nationally peer-reviewed study, intentional abuse and misuse reported to the National Poison Data System (NPDS) were tracked through the year 2020.


The investigation results published today in the peer-reviewed journal "Clinical Toxicology" have found that there were over 338,000 incidents of intentional abuse or misuse in American children aged 6 to 18 years old.


Most of the cases occurred in males (58.3%), with over 80% of all reported cases of exposure occurring in young individuals aged between 13 and 18. Overall, more than 32% of instances resulted in clinical outcomes worse than minor.


A new report has revealed changes in patterns over time. For instance, during the research period, Ritalin was the substance with the most reported use, but it peaked in 2006 and has since declined.


Furthermore, the year 2000 had the highest number of abuse cases involving contact with ethanol, but since then, incidents of children drinking alcohol have steadily declined over the years.


In contrast, cases of marijuana exposure remained relatively stable from the year 2000 to 2009 and then began to steadily increase from 2011 onwards, with an even greater increase in cases observed from the years 2017 to 2020.


Experts analyzing data attribute the increase in marijuana use to the growing popularity of edible marijuana products, which are now widely used throughout the country.


According to Dr. Adrienne Hughes, an assistant professor of emergency medicine at Oregon Health & Science University and one of the authors of the study, from 2000 to 2013, the number of cases of ethanol abuse exceeded the number of cases involving marijuana each year.


However, by 2014, this trend had reversed.


Since 2014, cases of exposure to marijuana have exceeded cases of exposure to alcohol every year, and the numbers have been increasing each year," said Hughes.


Though all rates of marijuana abuse are on the rise, the average monthly growth rate of marijuana consumption is the highest when compared with all other forms. This indicates that teenagers have shifted from smoking marijuana to other methods of consumption. Marijuana extracts, such as those used in marijuana electronic cigarette products, are also increasingly popular.


Hughes said, "These edible and electronic vaping products are typically marketed in a way that appeals to young people and are considered more independent and convenient.


Nevertheless, despite being perceived as having minimal harm, studies indicate that this is not necessarily the case.


According to Hughes, "While smoking marijuana typically leads to an immediate high, consuming it in an edible form can take several hours to take effect, which may cause some people to consume more and experience unexpected and unpredictable highs.


Since 2017, there has been a sharp increase in the number of children using marijuana, coinciding with a wave of decriminalization legislation in the United States. As of 2022, marijuana is legal for adult recreational use in 19 states and legal for medical use in 36 states.


Although marijuana is only legal for adults and not for children, the authors of this study argue that it makes it easier for children and adolescents to come into contact with the drug, and leads people to believe that it is safe.


Our research describes the rising trend of adolescent marijuana abuse, particularly those involving edible products," said Hughes.


These survey results highlight continued concern among people about the impact of rapid marijuana legalization on this vulnerable population.


In addition to marijuana, the study also revealed cases of teenage abuse of non-prescription drugs. Between 2001 and 2016, the highest number of drug abuse cases were related to dextromethorphan, a non-prescription cold and cough medication. Oral antihistamines were also among the most commonly abused drugs in this study.


Deaths caused by drug abuse are rare, occurring in only 0.1% of cases among 450 young people. The incidence of death is higher among males and teenagers aged 16-18. Opioids are most commonly associated with these deaths.


Furthermore, although there were 57,488 incidents involving children aged 6 to 12, these cases typically do not involve "traditional" drugs but rather vitamins, plants, melatonin, hand sanitizer, and other items.


The limitations of this study are restricted to exposure cases categorized as abuse or misuse. "It is possible that other cases of misuse or abuse may have been classified in another manner and therefore missed," the authors report.


2FIRSTS will continue to follow and report on this topic. Further updates will be posted on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
Japan Survey Finds 49.5% Would Cut Tobacco Use if Prices Rise, 64.6% Show Interest in Nicotine-Free Alternatives
A September online survey commissioned by Japanese smoking-accessories company Lightec found that 49.5% of respondents would consider reducing tobacco use if prices rose further, while 25.1% would consider switching to cheaper brands and 14.5% would consider using or combining alternatives such as vapes and nicotine-free herbal sticks. Another 64.6% expressed some level of interest in such alternatives. The survey covered 1,088 respondents aged 20 to 70 and was conducted by a company that sells NICOLESS nicotine-free vaping and herbal-stick products, meaning its findings should not be treated as representative of Japan's smoking population.
DATA
Oct.12
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12